Solid Biosciences said Thursday that the US Food and Drug Administration has granted fast track designation to SGT-003, the company s Duchenne muscular dystrophy gene therapy candidate. The.
On November 29, Annie and Ilan Ganot P’26, co-founders of Solid Biosciences, a Boston-based biotechnology company, gave an inspiring presentation to the CA community. They shared how they are developing treatments for Duchenne muscular dystrophy, a progressive and life-limiting muscle-wasting disease that afflicts approximately 10,000 boys in the United States alone, including their son. The Ganots shared how they leveraged their expertise, networks, and unrelenting drive as parents and professionals to push boundaries in science and technology to improve the lives of patients living with Duchenne.
Solid Biosciences (NASDAQ:SLDB – Get Free Report) and Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. Profitability This table compares Solid Biosciences […]
Comparing Finch Therapeutics Group (NASDAQ:FNCH) and Solid Biosciences (NASDAQ:SLDB) etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
By Denny Jacob Getty Images Holdings lowered its 2023 outlook, citing challenges ranging from strikes in Hollywood to a stronger dollar. Shares retreat 5.8%.